Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine
NorAziyah Mat Rahim1,2,3, HaiYen Lee1, Ulrich Strych2
1Tropical Infectious Diseases Research and Education Center (TIDREC), Universiti Malaya, Kuala Lumpur, Malaysia.
Abstract:
In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need for novel alternative approaches to the control of this bacterium becomes imperative. Vaccines against numerous bacteria have had impressive records in reducing the burden of the respective diseases and addressing antimicrobial resistance; as in the case of Haemophilus influenzae type b . A similar approach could be appropriate for A. baumannii. Toward this end, several potentially protective antigens against A. baumannii were identified and evaluated as vaccine antigen candidates. A licensed vaccine for the bacteria, however, is still not in sight. Here we explore and discuss challenges in vaccine development against A. baumannii and the promising approaches for improving the vaccine development process.
Insights
Developing vaccines against Acinetobacter baumannii (A. baumannii), a priority pathogen, is crucial due to limited treatment options. This research explores challenges and promising strategies for effective A. baumannii vaccines.
Area of Science:
- Microbiology and Immunology
- Vaccine Development
- Antimicrobial Resistance
Background:
- Acinetobacter baumannii (A. baumannii) is a critical global health threat, identified by the WHO as a priority pathogen due to its high antibiotic resistance.
- Limited last-resort treatment options, including polymyxin and tigecycline, highlight the urgent need for alternative control strategies against A. baumannii.
- Vaccination has proven effective against other bacterial pathogens, such as Haemophilus influenzae type b, suggesting its potential utility for A. baumannii.
Purpose of the Study:
- To investigate the challenges hindering the development of a licensed vaccine against Acinetobacter baumannii.
- To explore and discuss promising approaches that could accelerate and improve the vaccine development process for A. baumannii.
- To identify and evaluate potential vaccine antigen candidates for Acinetobacter baumannii.
Main Methods:
- Review and analysis of existing research on Acinetobacter baumannii vaccine development.
- Identification and evaluation of potential protective antigens for A. baumannii vaccine candidates.
- Discussion of challenges encountered in preclinical and clinical vaccine development stages.
Main Results:
- Several promising vaccine antigen candidates against A. baumannii have been identified and evaluated.
- Significant challenges remain in the development pathway, preventing the licensing of an effective A. baumannii vaccine.
- The study highlights the need for novel strategies to overcome existing hurdles in A. baumannii vaccine development.
Conclusions:
- Vaccine development presents a viable strategy to combat Acinetobacter baumannii infections and address antimicrobial resistance.
- Overcoming current challenges requires innovative approaches and continued research into effective vaccine antigen discovery and development.
- Further investigation into promising strategies is essential to bring a much-needed A. baumannii vaccine to fruition.
More Related Videos
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
Related Concept Videos
01:30Development of Antibiotic Resistance
01:29Microorganisms in Medicine and Therapeutics
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...